• In early June 2026, CareDx reported Q1 revenue growth of 39% year over year, raised full-year guidance to US$447–US$465 million with adjusted EBITDA of US$43–US$57 million, advanced its AI-enabled transplant diagnostics, and agreed to acquire Naveris while its CEO Hanna John Walter JR sold 4,835 shares as part of ongoing insider sales.
• The Naveris deal shifts CareDx further into oncology minimal residual disease testing with Medicare-covered NavDx and a planned AlloHeme launch for AML and MDS relapse monitoring, aligning the business more tightly with high-precision, recurring-test diagnostics.
• We’ll now examine how the Naveris acquisition and oncology expansion reshape CareDx’s existing investment narrative and future business mix.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

CareDx Investment Narrative Recap

To own CareDx, you need to believe its transplant testing and newer oncology MRD platform can keep attracting reimbursed volume while managing reimbursement and execution risks. Right now, the key near term catalyst is continued uptake of core testing services and margin progression, and the most immediate risk remains potential reimbursement pressure across its portfolio; the Naveris deal and Q1 beat do not materially change that risk, but they broaden where that risk sits.

The most relevant recent update here is CareDx’s raised 2026 guidance to US$447–US$465 million in revenue and US$43–US$57 million in adjusted EBITDA. Paired with the Naveris acquisition and oncology push, this frames how much financial headroom the company currently sees as it leans into AI-enabled diagnostics and MRD testing, and how sensitive that outlook still is to any shift in Medicare or broader payer reimbursement policies.

Yet even with this growth story, investors should be aware that reimbursement shifts or bundled payments could still...

CareDx's narrative projects $524.6 million revenue and $49.9 million earnings by 2029. This requires 8.3% yearly revenue growth and a $58.1 million earnings increase from -$8.2 million today.

Uncover how CareDx's forecasts yield a $25.80 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling about US$505.4 million in revenue and US$8.9 million in earnings by 2028, so this new oncology move and any reimbursement changes could either support that upside story or challenge it, depending on how you think those risks play out.

Explore 3 other fair value estimates on CareDx - why the stock might be worth just $25.80!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free CareDx research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CareDx's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.